10x Genomics (TXG) Return on Capital Employed (2019 - 2026)

10x Genomics has disclosed Return on Capital Employed across 8 years of filings, most recently posting 4.23% for Q1 2026.

• Return on Capital Employed for Q1 2026 came in at 4.23%, up 1724.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 4.23% (up 1724.0% YoY), and the FY2025 annual result was 7.38%, up 1623.0% from the prior year.
• Return on Capital Employed came in at 4.23% for Q1 2026 at 10x Genomics, up from 6.92% in the prior quarter.
• In the past five years, Return on Capital Employed ranged from a high of 4.23% in Q1 2026 to a low of 32.9% in Q1 2024.
• The 5-year median for Return on Capital Employed is 19.59% (2023), against an average of 19.31%.
• Across the five-year window, Return on Capital Employed soared 5473 bps in 2022 and plunged 1331 bps in 2024, its largest moves.
• 10x Genomics' Return on Capital Employed stood at 19.05% in 2022, then sank by 68 bps to 31.98% in 2023, then grew by 25 bps to 24.0% in 2024, then jumped by 71 bps to 6.92% in 2025, then surged by 39 bps to 4.23% in 2026.
• The last three Return on Capital Employed figures came in at 4.23% (Q1 2026), 6.92% (Q4 2025), and 10.66% (Q3 2025), per Business Quant data.